Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alendronic acid + cholecalciferol
- Development stage
- Phase 3
- Lead developer
- Obsons Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Obiferol is a fixed-dose combination tablet containing alendronic acid and cholecalciferol (vitamin D3). Developed by Obsons Pharmaceuticals, it is indicated for the treatment and prevention of osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis. Alendronic acid is a nitrogen-containing bisphosphonate that inhibits farnesyl pyrophosphate synthase (FDPS) in osteoclasts, thereby suppressing bone resorption and reducing bone turnover. Cholecalciferol is a vitamin D3 precursor that is metabolized to its active form, calcitriol, which binds to the vitamin D receptor (VDR) to enhance intestinal calcium absorption and support bone mineralization. This combination ensures that patients receiving bisphosphonate therapy maintain adequate vitamin D levels to optimize bone health.
- Brand names
- Obiferol
- Other names
- alendronate + cholecalciferolalendronate + vitamin d3alendronate sodium + cholecalciferolalendronic acid + vitamin d3
02
Targets
VDR (Vitamin D receptor)FDPS (Farnesyl pyrophosphate synthase)RXRA (Retinoid X receptor alpha)
Beyond the preview
Go deeper on alendronic acid + cholecalciferol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alendronic acid + cholecalciferol.